TCWP’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

TCWP’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-37	Closed	-$2K	–	1836
2022 Q1	$2K	Buy	+37	New	+$1.92K	﹤0.01%	1413

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCWP's ITCI Position: Q2 2022 in Review

TCWP sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2022, closing a stake of 37 shares — an estimated $2K sold.

TCWP first reported a position in ITCI in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 266 funds tracked by Wall St. Rank hold ITCI as of Q2 2022.

TCWP reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2022 after selling out during the quarter.
TCWP sold 37 Intra-Cellular Therapies Inc. shares in Q2 2022, an estimated $2K.
TCWP first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 1 quarter.
TCWP's Intra-Cellular Therapies Inc. position peaked at $2K in Q1 2022.
266 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.